Business Context and Reporting Period
This Form 8-K Current Report is filed by Intelligent Bio Solutions Inc. (INBS), a Delaware corporation and emerging growth company, for the reporting period ending March 18, 2026. The filing primarily addresses executive and director compensation arrangements and updates regarding the company's At-The-Market (ATM) equity offering program.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, net income, operating cash flow, or debt levels. However, it discloses the following capital structure data as of March 23, 2026:
- Shares Outstanding: 2,001,173 shares of Common Stock.
- ATM Offering Capacity: Up to $3,966,316 of shares available for sale under the 2026 ATM Supplement.
- Total ATM Program Limit: The offering is part of a broader $100,000,000 shelf registration (Form S-3).
Material Changes and Compensation Grants
On March 18, 2026, the Board of Directors approved significant equity grants under the 2019 Long Term Incentive Plan to directors, officers, and employees. Key grants include:
- CEO (Harry Simeonidis):
- 9,150 time-vesting restricted shares (vesting over 48 months).
- 21,350 performance-vesting restricted shares.
- CFO (Spiro Sakiris):
- 9,150 time-vesting restricted shares (vesting over 48 months).
- 21,350 performance-vesting restricted shares.
- Non-Executive Directors: Aggregate of 20,000 time-vesting restricted shares (vesting over 12 months).
- Non-Executive Employees: Aggregate of 10,500 time-vesting shares and 24,500 performance-vesting shares.
Performance Vesting Milestones: Performance shares vest based on three tranches: 30% upon a clinical trial milestone, 40% upon FDA regulatory submission completion, and 30% upon commercial supply and sales milestones. Unachieved conditions by the tenth anniversary result in forfeiture.
Outlook, Risks, and Unusual Items
ATM Offering Update: The company filed a 2026 ATM Supplement to offer and sell additional shares with an aggregate gross sales price of up to $3,966,316. This follows a previous supplement filed in September 2025 for up to $1,211,174. Sales are conducted via Ladenburg Thalmann & Co. Inc.
Risks and Contingencies:
- Dilution Risk: The ATM program allows for the issuance of additional shares, which may dilute existing shareholders.
- Forfeiture Risk: Performance-based equity awards are contingent on specific clinical, regulatory, and commercial milestones; failure to meet these by the tenth anniversary results in share forfeiture.
- Clawback Policy: All awards are subject to the company's clawback policy.
Investor Verification Checklist
- Verify the current market price of INBS to assess the dilution impact of the $3,966,316 ATM offering capacity.
- Review the specific clinical trial and regulatory milestones defined in the performance vesting agreements (Exhibits 10.3 and 10.6) to gauge the likelihood of vesting.
- Confirm the total number of authorized but unissued shares to understand the remaining capacity for future equity raises.
- Check subsequent filings for any sales executed under the ATM program since March 23, 2026.